Blog

The role of flow cytometry in CAR-T therapy

A recent article published by a Senior Scientist in Cell Therapies at Takeda Oncology in American Pharmaceutical Review outlined the critical importance of flow cytometry-based analytical assays in the development and manufacturing of CAR-T therapies. The application of flow cytometry in this field is an FDA requirement – yet flow cytometry has some well-known drawbacks, […]

An interview with Satnam Surae, Chief Product Officer at Aigenpulse

It’s been a busy few months for the team here at Aigenpulse as we work on releasing some updates to our CytoML Suite. We managed to grab our Chief Product Officer, Satnam Surae, for a quick chat about how automation can help the pharma industry leverage data analytics and advanced machine learning to uncover insights […]

The future of flow cytometry: from semi-automated gating to unbiased analysis

Commercial flow cytometry methods have been used in basic research and clinical diagnostics labs since the 1970s, primarily for immunology and haematology applications, and, more recently, its benefits have been realised at various stages of pre-clinical and clinical drug discovery and development. It has become a critical technology, with a global market valued at USD […]

Automated vs manual gating in flow cytometry: potential game changer?

With a constant increase in demand for new drugs, pharmaceutical companies face pressure to continuously expand their research and development (R&D) efforts. Flow cytometry is a diverse and crucial technique in pharmaceutical research, used to investigate disease aetiology and alterations in immune responses, as well as for quantitative studies. Flow cytometry has the potential to […]

Automated flow cytometry gating shows promise in Covid-19 immune response study

Understanding the immunophenotype of Covid-19 patients could play a key role in anticipating the course of the disease in a patient, thereby assisting healthcare professionals in making critical personalised treatment decisions. In collaboration with Guy’s and St Thomas’ NHS Foundation Trust and the Francis Crick Institute in London, and the European Bioinformatics Institute (EMBL-EBI) in […]

The biopharma and biotech digital refresh – building advantage for the post-COVID future

The extensive amount of data available within drug development pipelines poses a significant challenge for scientists trying to derive insights. The range of different techniques being used generates data in many different formats and sizes – creating difficulties when structuring, sharing, and analysing the research. It has been estimated that two thirds of researchers’ time […]